Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [14C]-Retatrutide in Healthy Males
NCT05757531Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of retatrutide in obesity and type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Fecal Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Mar 2023; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05757531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757531.